Reconsidering tolerability of cancer treatments: opportunities to focus on the patient.
Reconsidering tolerability of cancer treatments: opportunities to focus on the patient.
复制标题
DOI：
10.1007/s00520-021-06700-0
复制
发表时间：
2022-05
影响因子：
3.1
通讯作者：
Smith, Mary Lou
中科院分区：
文献类型：
--
作者：
Peipert, John Devin;Smith, Mary Lou
在评估癌症治疗的耐受性时，已经出现了增加患者发言权的重大举措[1]。传统的耐受性评估依赖于临床医生使用国家癌症研究所的不良事件通用术语标准 (CTCAE) 评定的毒性。癌症之友最近发表的一份白皮书提出了从患者角度评估耐受性的能力：“医疗产品的耐受性是指与产品使用相关的症状和非症状不良事件影响患者坚持治疗剂量或强度的能力或愿望的程度。对耐受性的完整理解应包括直接测量患者在治疗期间的感受和功能。”[2] 这一定义在之前对耐受性的考虑的基础上进行了改进。最重要的是，它将焦点转移到患者对治疗的反应的感觉或功能上。这还意味着耐受性是通过患者报告评估的。我们同意并支持这种新的、以患者为导向的耐受性定义，但我们相信有重要的机会来扩展它。之友的定义完全侧重于治疗经验，这很重要，但仅涵盖患者接受治疗时发生的情况。此外，甚至在开始治疗之前就需要了解患者的情况，以表明他们的耐受性。从这个角度来看，我们的重点是揭示除了患者体验之外，患者性格在捕捉治疗耐受性方面的重要性。
There has been a significant movement toward increasing the patient’s voice in assessment of tolerability of cancer treatments [1]. Traditional assessment of tolerability has relied on clinician-rated toxicities, using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). A recent white paper published by the Friends of Cancer advanced the ability to assess tolerability from the patient’s perspective:“The tolerability of a medical product is the degree to which symptomatic and non-symptomatic adverse events associated with the product’s administration affect the ability or desire of the patient to adhere to the dose or intensity of therapy. A complete understanding of tolerability should include direct measurement from the patient on how they are feeling and functioning while on treatment.”[2] This definition improves upon previous considerations of tolerability. Most importantly, it shifts focus to how a patient feels or functions in response to their treatments. It also implies that tolerability is assessed via patient report. We agree with and support this new, patient-oriented definition of tolerability, but we believe there are important opportunities to expand it. The Friends’ definition focuses exclusively on experience with treatment, which is critical but captures only what happens while the patient is on treatment. In addition, there is a need to capture what the patient is bringing to the table even before starting treatment that can indicate their tolerability. Our focus in this perspective is to reveal the importance of the patient disposition in addition to the patient experience in capturing treatment tolerability.
登录
查看更多内容
影响因子：
28.4
作者：
Dueck AC;Mendoza TR;Mitchell SA;Reeve BB;Castro KM;Rogak LJ;Atkinson TM;Bennett AV;Denicoff AM;O'Mara AM;Li Y;Clauser SB;Bryant DM;Bearden JD 3rd;Gillis TA;Harness JK;Siegel RD;Paul DB;Cleeland CS;Schrag D;Sloan JA;Abernethy AP;Bruner DW;Minasian LM;Basch E;National Cancer Institute PRO-CTCAE Study Group
通讯作者：
National Cancer Institute PRO-CTCAE Study Group
影响因子：
4.5
作者：
Kluetz, Paul G.;Kanapuru, Bindu;Coons, Stephen Joel
通讯作者：
Coons, Stephen Joel
影响因子：
3.8
作者：
Wagner LI;Zhao F;Goss PE;Chapman JW;Shepherd LE;Whelan TJ;Mattar BI;Bufill JA;Schultz WC;LaFrancis IE;Nagargoje GG;Vemuri R;Nikcevich DA;Sledge GW;Cella D
通讯作者：
Cella D
DOI：
10.1177/1740774520975120
发表时间：
2021-03
期刊：
Clinical trials (London, England)
影响因子：
--
作者：
Basch E;Becker C;Rogak LJ;Schrag D;Reeve BB;Spears P;Smith ML;Gounder MM;Mahoney MR;Schwartz GK;Bennett AV;Mendoza TR;Cleeland CS;Sloan JA;Bruner DW;Schwab G;Atkinson TM;Thanarajasingam G;Bertagnolli MM;Dueck AC
通讯作者：
Dueck AC
影响因子：
6.2
作者：
Pearman, Timothy P.;Beaumont, Jennifer L.;Cella, David
通讯作者：
Cella, David